Pine Valley Investments Ltd Legal responsibility Co lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.8% through the second quarter, Holdings Channel.com reviews. The agency owned 4,752 shares of the medical analysis firm’s inventory after promoting 237 shares through the quarter. Pine Valley Investments Ltd Legal responsibility Co’s holdings in Amgen had been value $1,485,000 as of its most up-to-date SEC submitting.
Different institutional buyers additionally lately added to or diminished their stakes within the firm. Searle & CO. bought a brand new stake in Amgen within the second quarter valued at about $2,256,000. Hantz Monetary Companies Inc. bought a brand new stake in Amgen within the second quarter valued at about $343,000. Arrow Monetary Corp raised its stake in Amgen by 36.9% within the second quarter. Arrow Monetary Corp now owns 13,065 shares of the medical analysis firm’s inventory valued at $4,082,000 after shopping for a further 3,524 shares over the past quarter. Kings Path Companions LLC bought a brand new stake in Amgen within the second quarter valued at about $1,365,000. Lastly, GoalVest Advisory LLC raised its stake in Amgen by 27.0% within the second quarter. GoalVest Advisory LLC now owns 682 shares of the medical analysis firm’s inventory valued at $213,000 after shopping for a further 145 shares over the past quarter. Institutional buyers personal 76.50% of the corporate’s inventory.
Amgen Inventory Up 0.9 %
Shares of AMGN inventory opened at $333.83 on Friday. The inventory has a 50 day transferring common of $324.99 and a 200 day transferring common of $300.71. The corporate has a present ratio of 1.42, a fast ratio of 0.98 and a debt-to-equity ratio of 11.96. The inventory has a market cap of $179.08 billion, a P/E ratio of 47.69, a P/E/G ratio of two.78 and a beta of 0.58. Amgen Inc. has a twelve month low of $248.38 and a twelve month excessive of $346.85.
Amgen (NASDAQ:AMGN – Get Free Report) final issued its quarterly earnings knowledge on Tuesday, August sixth. The medical analysis firm reported $4.97 EPS for the quarter, lacking the consensus estimate of $5.01 by ($0.04). Amgen had a web margin of 12.74% and a return on fairness of 156.21%. The enterprise had income of $8.39 billion through the quarter, in comparison with analyst estimates of $8.35 billion. Throughout the identical interval within the earlier yr, the enterprise posted $5.00 earnings per share. The agency’s income for the quarter was up 20.1% on a year-over-year foundation. As a gaggle, sell-side analysts count on that Amgen Inc. will publish 19.5 EPS for the present yr.
Amgen Broadcasts Dividend
The agency additionally lately disclosed a quarterly dividend, which was paid on Tuesday, August sixth. Shareholders of report on Friday, August sixteenth had been issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of two.70%. The ex-dividend date of this dividend was Friday, August sixteenth. Amgen’s payout ratio is presently 128.57%.
Analysts Set New Value Targets
Quite a few equities analysis analysts have commented on AMGN shares. TD Cowen elevated their worth goal on Amgen from $360.00 to $381.00 and gave the corporate a “purchase” ranking in a analysis notice on Wednesday, August seventh. Morgan Stanley diminished their worth goal on Amgen from $310.00 to $303.00 and set an “equal weight” ranking for the corporate in a analysis notice on Thursday, July eleventh. Oppenheimer restated an “outperform” ranking and issued a $380.00 worth goal on shares of Amgen in a analysis notice on Wednesday, August seventh. Mizuho raised their worth goal on Amgen from $223.00 to $235.00 and gave the inventory a “impartial” ranking in a analysis notice on Thursday, Might ninth. Lastly, Royal Financial institution of Canada raised their worth goal on Amgen from $332.00 to $362.00 and gave the inventory an “outperform” ranking in a analysis notice on Wednesday, August seventh. Eleven funding analysts have rated the inventory with a maintain ranking and twelve have given a purchase ranking to the corporate. In accordance with knowledge from MarketBeat, the corporate presently has a consensus ranking of “Average Purchase” and a consensus worth goal of $326.89.
Get Our Newest Inventory Report on Amgen
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The corporate’s principal merchandise embody Enbrel to deal with plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the remedy of grownup sufferers with plaque psoriasis, psoriatic arthritis, and oral ulcers related to Behçet’s illness; Prolia to deal with postmenopausal ladies with osteoporosis; XGEVA for skeletal-related occasions prevention; Repatha, which reduces the dangers of myocardial infarction, stroke, and coronary revascularization; Nplate for the remedy of sufferers with immune thrombocytopenia; KYPROLIS to deal with sufferers with relapsed or refractory a number of myeloma; Aranesp to deal with a lower-than-normal variety of crimson blood cells and anemia; EVENITY for the remedy of osteoporosis in postmenopausal for women and men; Vectibix to deal with sufferers with wild-type RAS metastatic colorectal most cancers; BLINCYTO for the remedy of sufferers with acute lymphoblastic leukemia; TEPEZZA to deal with thyroid eye illness; and KRYSTEXXA for the remedy of continual refractory gout.
See Additionally
Wish to see what different hedge funds are holding AMGN? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Obtain Information & Scores for Amgen Day by day – Enter your electronic mail handle under to obtain a concise each day abstract of the newest information and analysts’ rankings for Amgen and associated firms with MarketBeat.com’s FREE each day electronic mail publication.
